Telephone
61.2.8667.5337
Address
Suite 4.01 65 Epping Road Macquarie Park, New South Wales (NSW) 2113
Description
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. It is developing portable electromagnetic tomography solutions. EMvision Medical Devices was founded on July 11, 2017 and is headquartered in Brisbane, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.13 - 2.12
Trade Value (12mth)
AU$13,073.00
1 week
4.61%
1 month
3.25%
YTD
-8.88%
1 year
-20.5%
All time high
4.2
EPS 3 yr Growth
-12.000%
EBITDA Margin
N/A
Operating Cashflow
$1m
Free Cash Flow Return
12.80%
ROIC
-59.30%
Interest Coverage
-300.10
Quick Ratio
1.70
Shares on Issue (Fully Dilluted)
78m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 May 23 |
Leadership Transition
×
Leadership Transition |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 August 21 |
Appendix 4E & Annual Report 30 June 2021
×
Appendix 4E & Annual Report 30 June 2021 |
30 November 22 |
EMVision Commences Clinical Trial
×
EMVision Commences Clinical Trial |
30 August 23 |
Appendix 4E & Annual Report to 30 June 2023
×
Appendix 4E & Annual Report to 30 June 2023 |
30 August 23 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
30 August 22 |
Appendix 4E & Annual Report to 30 June 2022
×
Appendix 4E & Annual Report to 30 June 2022 |
30 August 22 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
30 August 19 |
Appendix 4E & Annual Report 30 June 2019
×
Appendix 4E & Annual Report 30 June 2019 |
29 September 23 |
Notification of cessation of securities - EMV
×
Notification of cessation of securities - EMV |
29 September 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
29 May 23 |
Stage 2 of Clinical Trial Activated
×
Stage 2 of Clinical Trial Activated |
29 June 23 |
Recruitment at Royal Melbourne Hospital Commences
×
Recruitment at Royal Melbourne Hospital Commences |
29 June 22 |
Application for quotation of securities - EMV
×
Application for quotation of securities - EMV |
29 June 22 |
Cleansing Notice
×
Cleansing Notice |
29 August 22 |
$5m Modern Manufacturing Initiative Grant Proceeding
×
$5m Modern Manufacturing Initiative Grant Proceeding |
29 April 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 July 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 February 23 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
28 February 23 |
CEO Half-Year Update
×
CEO Half-Year Update |
27 October 20 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
27 November 23 |
Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled
×
Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled |
27 June 22 |
EMVision Achieves First Responder Milestone
×
EMVision Achieves First Responder Milestone |
27 July 23 |
Clinical Trial Progress & ASA Milestone Achieved
×
Clinical Trial Progress & ASA Milestone Achieved |
27 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.